Telix share price slides despite 726% revenue boost

Investors may be thinking the pharmaceutical company's valuation has peaked after the stock price doubled over the past three months.

| More on:
A CSL scientist looking through a telescope in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Telix released its results for the half-year ending 30 June
  • In April, the company publicly released its flagship product Illuccix in the US
  • Revenue and cash all rocketed as the first commercial sales of Illucix came in

The Telix Pharmaceuticals Ltd (ASX: TLX) share price plunged in early trade on Thursday after the company revealed its results for the half-year ending 30 June.

Shares in the ASX biotech company are currently trading down 4.1% at $6.96 after touching an intraday low of $6.66 this morning.

What did the company report?

  • Revenue up 726% to hit $24 million
  • Loss after income tax attributable to shareholders up 118% to $70.9 million
  • Cash at the end of the half-year 456% higher to hit $122.6 million
  • Global sales of Illuccix were $22.5 million.

What else happened in the half-year?

The major highlight for Telix in the first half of the calendar year 2022 was arguably the biggest milestone in the company's history. That was the commercial launch of its prostate cancer product Illuccix in April, which triggered an 11% share price gain that morning.

The product is now available in 149 pharmacies across the United States, which brought in $19.3 million in sales.

What did management say?

Telix chair Kevin McCann and chief executive Christian Behrenbruch jointly released a statement saying:

Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical [needs] in oncology and rare diseases.

The principal activities of the group during the half-year were directed to the first commercial sales of Illuccix in the United States and the further development of the group's pipeline of radiopharmaceutical products, including completion of recruitment into the company's phase III pivotal clinical trial of TLX250-CDx for renal cancer imaging.

What's next?

The company did not provide specific guidance for the second half or the full year.

Telix is currently working through approvals to commercially release Illuccix in Australia, Europe, the United Kingdom, Canada, South Korea and China. The product already has commercial approval for the New Zealand market.

The pharma company is also working on solutions for other cancers, such as renal and bone marrow.

Telix share price snapshot

The Telix share price has been on a wild ride this year.

It started 2022 at around $8.22 but was caught up in the brutal sell-off of high-growth and biotechnology shares to plunge to $3.55 by mid-May.

But since then, the commercial release of Illuccix seems to have caught investors' attention, with the stock more than doubling in just three months.

Motley Fool contributor Tony Yoo has positions in TELIXPHARM DEF SET. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A man sits on a bench atop a mountain with a laptop, making investments with a green ESG mind.
Earnings Results

ASX All Ords stock KMD tumbles as interim dividend cancelled

Investors are hitting the sell button on ASX All Ords stock KMD today.

Read more »

Coal miner holding a giant coal rock in his hand making a circle with his hand, symbolising a rising share price.
Energy Shares

New Hope share price charges higher despite profit crunch and huge dividend cut

Weaker coal prices have hit this miner's profits and dividend hard.

Read more »

A Chinese investor sits in front of his laptop looking pensive and concerned about pandemic lockdowns which may impact ASX 200 iron ore share prices
Earnings Results

Liontown share price tumbles 7% on half-year results

This lithium developer's results have been released this afternoon.

Read more »

A man in a hard hat and high visibility vest holds his thumb up in a gesture of confidence with heavy moving equipment in the background as on a mine site as the Chalice Mining share price rises today.
Earnings Results

Sayona Mining share price jumps despite $32m half-year loss

The Sayona Mining Ltd (ASX: SYA) share price is pushing higher on Thursday. At the time of writing, the lithium…

Read more »

Photo of two women shopping.
Earnings Results

Myer share price charges higher on half-year results and major board changes

This department store operator reported a sharp profit decline but investors don't mind.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Materials Shares

Core Lithium shares crash 9% after posting massive half-year loss

This lithium miner is having a very tough time due to weak prices.

Read more »

a woman with her hands over her face splits her fingers over one eye so she can peep through them.
Materials Shares

Core Lithium share price on watch amid $167m half-year loss and CEO exit

All eyes will be on this lithium miner tomorrow after it post a huge loss.

Read more »

A group of business people in a board room hear the latest company report
Earnings Results

Key takeouts for ASX shares this earnings season: CBA analysis

Profits were weaker but plenty of dividends were splashed about this earnings season.

Read more »